Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, randomised, double-blind, parallel-group, comparative study to compare the efficacy and safety of esomeprazole 20 mg once daily oral administration with omeprazole 10 mg and esomeprazole 10 mg once daily oral administration in maintenance treatment in patients with healed reflux esophagitis

Trial Profile

A multicentre, randomised, double-blind, parallel-group, comparative study to compare the efficacy and safety of esomeprazole 20 mg once daily oral administration with omeprazole 10 mg and esomeprazole 10 mg once daily oral administration in maintenance treatment in patients with healed reflux esophagitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esomeprazole (Primary) ; Omeprazole
  • Indications Reflux oesophagitis
  • Focus Therapeutic Use
  • Sponsors AstraZeneca

Most Recent Events

  • 06 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 06 Oct 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
  • 06 Oct 2009 Actual patient number (540) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top